Clinical Trials Logo

Filter by:
NCT ID: NCT06294301 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Start date: November 19, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-005 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06294184 Recruiting - Clinical trials for Transcranial Direct Current Stimulation

tDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals.

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the mechanisms of the effect of transcranial direct current stimulation (tDCS) in alleviating subthreshold depressive symptoms in young individuals, and individualized outcome prediction is carried out.

NCT ID: NCT06293378 Recruiting - Cirrhosis, Liver Clinical Trials

Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, changes in fecal flora and metabolites before and after the use of sulfasalazine were observed.

NCT ID: NCT06293287 Recruiting - Clinical trials for Radial Artery Occlusion

Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

The present investigation is designed as a single-blind, randomized, controlled, bicentric trial. The objective is to ascertain whether the subcutaneous administration of enoxaparin sodium for prophylactic anticoagulation during transradial hepatic arterial infusion chemotherapy (HAIC) can diminish the incidence of radial artery occlusion (RAO) post-procedure

NCT ID: NCT06293196 Recruiting - Clinical trials for Investigating the Effects of Periocular Acupressure on Ocular Biological Indicators

Effects of Acupoint Massage Around Eyes on Ocular Biological Indexes

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate whether the acupoint eye exercise could impact the biological parameters of the eye.

NCT ID: NCT06293144 Recruiting - Sedation Clinical Trials

the 95% Effective Dose of Ciprofol for Adjunctive Sedation Undergoing Knee Arthroplasty in Elderly People

Start date: November 29, 2023
Phase: Early Phase 1
Study type: Interventional

Regional anesthesia is a common clinical anesthesia method, and regional anesthesia-assisted sedation play a central role in promoting patient comfort and relieving anxiety. With increasing age, elderly people experience changes in pharmacokinetics and pharmacodynamics and increased drug sensitivity. Ciprofol has advantages in adverse events such as hypotension and respiratory depression. There are fewer studies on the recommended dosage of ciprofol-assisted sedation for intrathecal anesthesia in elderly patients. The aim of study is to identify the 95% effective dose of ciprofol-assisted sedation in elderly patients undergoing spinal anesthesia using a biased coin design up-and-down sequential method(BCD-UDM)

NCT ID: NCT06293014 Recruiting - Colorectal Cancer Clinical Trials

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Start date: February 23, 2024
Phase: Phase 2
Study type: Interventional

This study is a randomized, controlled, open-label, multicentre clinical study. This study is designed to evaluate the efficacy and safety of TAS-102 combined with bevacizumab as second-line maintenance therapy versus standard chemotherapy combined with bevacizumab as second-line continuous therapy in advanced colorectal cancer after second-line induction therapy.

NCT ID: NCT06292949 Recruiting - Constipation Clinical Trials

Clinical Study of Resistant Starch in Improving Constipation

Start date: September 27, 2023
Phase: N/A
Study type: Interventional

Constipation is one of the most common gastrointestinal (GI) disorders in clinical practice, with approximately 11-20% of adults worldwide suffering from constipation. Clinically, the frequency of defecation is reduced, or the defecation is laborious, obstructed, difficult, and the stool is dry and difficult to solve, which is called constipation. Clinically, constipation is difficult to treat and over-reliance on laxatives often leads to water and electrolyte imbalance, gastrointestinal dysfunction, melanosis of the colon, relaxation of anal sphincter and other problems, and even leads to colorectal cancer, diabetes, anorexia nervosa and other complications in some cases. Therefore, it is very important to find a safe and effective laxative drug or diet to improve and relieve constipation symptoms. The health promotion effect of resistant starch is mainly due to the short-chain fat and gas produced by microbial fermentation in the colon, and its role in preventing colorectal cancer and some diet-related chronic diseases is stronger than dietary fiber, and it can effectively overcome the adverse odor, rough texture, poor quality and other drawbacks of food fortified with dietary fiber. Ruminococcus bromii is a specific microorganism that degrades resistant starch. The starch decomposing enzyme of R. bromii has a unique tissue structure and forms a multi-enzyme complex. Through the adhesion protein and dockerin module, it is attached to the cell surface through the scaffold protein in the cellulose body. Big data analysis showed that the relative abundance of R. bromii in healthy people was significantly higher than that in patients with constipation. Therefore, the purpose of this clinical trial is to supplement resistant starch to patients with constipation: (1) Observe whether the symptoms of patients with constipation have improved; (2) Analyze the changes of intestinal microorganisms in patients with constipation; and (3) Verify whether the relative abundance of R. bromii is increased and analyze the correlation between the relative abundance of R. bromii in intestine and the improvement of constipation symptoms in patients with constipation.

NCT ID: NCT06292858 Recruiting - Clinical trials for Recurrent or Metastatic, Advanced Solid Tumors

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

Start date: February 24, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Subjects with Recurrent or Metastatic,Advanced Solid Tumors

NCT ID: NCT06292715 Recruiting - Clinical trials for Secondary Hypersplenism

Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

This study assesses the effectiveness of microwave ablation of the spleen in conjunction with splenic artery occlusion for treating secondary hypersplenism.